• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

桂枝茯苓丸通过恢复 PI3K/AKT/mTOR 信号通路减少多囊卵巢综合征大鼠颗粒细胞自噬。

Guizhi Fuling Wan reduces autophagy of granulosa cell in rats with polycystic ovary syndrome via restoring the PI3K/AKT/mTOR signaling pathway.

机构信息

Chengdu University of Traditional Chinese Medicine, Chengdu City, Sichuan Province, China.

Department of Gynaecology, School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine / Reproductive & Women-Children Hospital of Chengdu University of Traditional Chinese, Chengdu City, Sichuan Province, 610041, China.

出版信息

J Ethnopharmacol. 2021 Apr 24;270:113821. doi: 10.1016/j.jep.2021.113821. Epub 2021 Jan 16.

DOI:10.1016/j.jep.2021.113821
PMID:33460753
Abstract

ETHNOPHARMACOLOGICAL RELEVANCE

Guizhi Fuling Wan (GFW) is a traditional Chinese medicine used to remove blood stasis and dissipate phlegm for treating gynecological diseases that was invented by Zhang Zhongjing in the Eastern Han dynasty. In recent years, GFW has been widely used to treat patients with polycystic ovary syndrome (PCOS). Clinical and animal studies have shown that it is effective in the treatment of PCOS, but its mechanism is unknown. Generally, it works by regulating autophagy via the PI3K/AKT/mTOR signaling pathway.

AIM OF THE STUDY

This study investigated the effects and mechanism of GFW in PCOS rats with insulin resistance (IR) in order to provide better understanding of its observed clinical effects and a theoretical basis for the study of traditional Chinese medicine.

MATERIALS AND METHODS

Eighty-four female Sprague-Dawley rats were randomly divided into seven groups (n = 12 per group): 1) control, 2) PCOS model, 3) low-dose GFW, 4) medium-dose GFW, 5) high-dose GFW, 6) metformin, and 7) medium-dose GFW plus LY294002. In all non-control groups, we induced PCOS through daily letrozole combined with intragastric high-fat emulsion for 21 days. After treatment, rats were sacrificed and serum follicle-stimulating hormone (FSH), testosterone (T), progesterone, luteinizing hormone (LH), 17β-estradiol, fasting insulin (FINS), and fasting plasma glucose levels were measured by enzyme-linked immunosorbent assay (ELISA). The LH/FSH ratios and HOMA-IR values were calculated. Ovarian morphology was observed by hematoxylin and eosin staining, and all follicles were counted under a microscope. MDC-positive vesicles were used as markers to detect autophagy, and the expression levels of p62, Beclin1, and LC3-II were examined by immunostaining. Western blotting was used to measure PI3K/AKT/mTOR pathway activation, granulosa cell apoptosis, and autophagy.

RESULTS

Compared with the PCOS model group, GFW-treated rats had less atretic and cystic follicles, and more mature follicles and corpus lutea. The GFW-treated rats had lower serum T, LH, and FINS levels than the PCOS model group, as well as lower LH/FSH ratios and HOMA-IR values. GFW treatment resulted in significantly reduced levels of cleaved-Caspase-3, cleaved-Caspase-9, BAX, Beclin1, Atg5, and LC3-II. Phosphorylation of PI3K, AKT, and mTOR was significantly higher in GFW-treated rats compared with the PCOS model group. The phosphorylation of PI3K, AKT, and mTOR was decreased with the use of a PI3K antagonist.

CONCLUSIONS

Our results indicate that GFW inhibited granulosa cell autophagy and promoted follicular development to attenuate ovulation disorder in PCOS-IR rats. This was associated with activation of the PI3K/AKT/mTOR signaling pathway.

摘要

民族药理学相关性

桂枝茯苓丸(GFW)是一种传统的中药方剂,用于活血化瘀、消痰散结,治疗妇科疾病,由东汉张仲景所创。近年来,GFW 被广泛用于治疗多囊卵巢综合征(PCOS)患者。临床和动物研究表明,它在治疗 PCOS 方面有效,但具体机制尚不清楚。一般来说,它通过调节自噬来发挥作用,而自噬是通过 PI3K/AKT/mTOR 信号通路来实现的。

研究目的

本研究旨在探讨 GFW 对胰岛素抵抗(IR)多囊卵巢综合征大鼠的作用及其机制,为其临床疗效提供更好的理解,并为中药研究提供理论依据。

材料和方法

84 只雌性 Sprague-Dawley 大鼠随机分为七组(每组 n = 12):1)对照组,2)PCOS 模型组,3)低剂量 GFW 组,4)中剂量 GFW 组,5)高剂量 GFW 组,6)二甲双胍组,7)中剂量 GFW 加 LY294002 组。所有非对照组大鼠均通过每日给予来曲唑联合灌胃高脂乳剂的方法诱导 PCOS,共 21 天。治疗结束后,处死大鼠,通过酶联免疫吸附试验(ELISA)检测血清卵泡刺激素(FSH)、睾酮(T)、孕酮、黄体生成素(LH)、17β-雌二醇、空腹胰岛素(FINS)和空腹血糖水平。计算 LH/FSH 比值和 HOMA-IR 值。通过苏木精和伊红(H&E)染色观察卵巢形态,在显微镜下计数所有卵泡。用 MDC 阳性囊泡作为标记物检测自噬,用免疫染色法检测 p62、Beclin1 和 LC3-II 的表达水平。用 Western blot 检测 PI3K/AKT/mTOR 通路的激活、颗粒细胞凋亡和自噬情况。

结果

与 PCOS 模型组相比,GFW 治疗组大鼠的闭锁和囊性卵泡减少,成熟卵泡和黄体增多。与 PCOS 模型组相比,GFW 治疗组大鼠的血清 T、LH 和 FINS 水平降低,LH/FSH 比值和 HOMA-IR 值降低。GFW 治疗组大鼠的 cleaved-Caspase-3、cleaved-Caspase-9、BAX、Beclin1、Atg5 和 LC3-II 表达水平明显降低。与 PCOS 模型组相比,GFW 治疗组大鼠的 PI3K、AKT 和 mTOR 的磷酸化水平明显升高。使用 PI3K 拮抗剂后,PI3K、AKT 和 mTOR 的磷酸化水平降低。

结论

本研究结果表明,GFW 通过抑制颗粒细胞自噬并促进卵泡发育来减轻 PCOS-IR 大鼠的排卵障碍,这与激活 PI3K/AKT/mTOR 信号通路有关。

相似文献

1
Guizhi Fuling Wan reduces autophagy of granulosa cell in rats with polycystic ovary syndrome via restoring the PI3K/AKT/mTOR signaling pathway.桂枝茯苓丸通过恢复 PI3K/AKT/mTOR 信号通路减少多囊卵巢综合征大鼠颗粒细胞自噬。
J Ethnopharmacol. 2021 Apr 24;270:113821. doi: 10.1016/j.jep.2021.113821. Epub 2021 Jan 16.
2
Liuwei Dihuang Pills alleviate the polycystic ovary syndrome with improved insulin sensitivity through PI3K/Akt signaling pathway.六味地黄丸通过 PI3K/Akt 信号通路改善胰岛素敏感性,从而缓解多囊卵巢综合征。
J Ethnopharmacol. 2020 Mar 25;250:111965. doi: 10.1016/j.jep.2019.111965. Epub 2019 Jun 8.
3
The ameliorating effects of Guizhi Fuling Wan combined with rosiglitazone in a rat ovarian model of polycystic ovary syndrome by the PI3K/AKT/NF-κB and Nrf2/HO-1 pathways.桂枝茯苓丸联合罗格列酮通过 PI3K/AKT/NF-κB 和 Nrf2/HO-1 通路对多囊卵巢综合征大鼠模型的改善作用。
Gynecol Endocrinol. 2023 Dec;39(1):2254848. doi: 10.1080/09513590.2023.2254848.
4
Acupuncture regulates the autophagy of ovarian granulosa cells in polycystic ovarian syndrome ovulation disorder by inhibiting the PI3K/AKT/mTOR pathway through LncMEG3.针刺通过 LncMEG3 抑制 PI3K/AKT/mTOR 通路调节多囊卵巢综合征排卵障碍患者卵巢颗粒细胞自噬。
Biomed Pharmacother. 2021 Dec;144:112288. doi: 10.1016/j.biopha.2021.112288. Epub 2021 Oct 13.
5
Bu-shen-zhu-yun decoction inhibits granulosa cell apoptosis in rat polycystic ovary syndrome through estrogen receptor α-mediated PI3K/AKT/mTOR pathway.补肾助孕汤通过雌激素受体 α 介导的 PI3K/AKT/mTOR 通路抑制多囊卵巢综合征大鼠颗粒细胞凋亡。
J Ethnopharmacol. 2022 Apr 24;288:114862. doi: 10.1016/j.jep.2021.114862. Epub 2021 Nov 30.
6
Guizhi Fuling Wan, Chinese Herbal Medicine, Ameliorates Insulin Sensitivity in PCOS Model Rats With Insulin Resistance via Remodeling Intestinal Homeostasis.桂枝茯苓丸,中药,通过重塑肠道稳态改善胰岛素抵抗多囊卵巢综合征模型大鼠胰岛素敏感性。
Front Endocrinol (Lausanne). 2020 Aug 27;11:575. doi: 10.3389/fendo.2020.00575. eCollection 2020.
7
Effect of berberine combined with metformin on autophagy in polycystic ovary syndrome by regulating AMPK/AKT/mTOR pathway.黄连素联合二甲双胍通过调节 AMPK/AKT/mTOR 通路对多囊卵巢综合征自噬的影响。
Mol Reprod Dev. 2024 Aug;91(8):e23768. doi: 10.1002/mrd.23768.
8
Cangfudaotan Decoction Alleviates Insulin Resistance and Improves Follicular Development in Rats with Polycystic Ovary Syndrome via IGF-1-PI3K/Akt-Bax/Bcl-2 Pathway.苍附导痰汤通过 IGF-1-PI3K/Akt-Bax/Bcl-2 通路改善多囊卵巢综合征大鼠胰岛素抵抗及卵泡发育。
Mediators Inflamm. 2020 Nov 24;2020:8865647. doi: 10.1155/2020/8865647. eCollection 2020.
9
Dingkun Pill replenishes diminished ovarian reserve through the PI3K/AKT/mTOR signaling pathway in TWP-induced mice.定坤丹通过 PI3K/AKT/mTOR 信号通路改善雷公藤多苷致卵巢储备功能下降模型小鼠的卵巢储备功能。
J Ethnopharmacol. 2020 Nov 15;262:112993. doi: 10.1016/j.jep.2020.112993. Epub 2020 May 28.
10
[Mechanism of Kuntai Capsules in treatment of polycystic ovary syndrome rat models based on AGE-RAGE signal pathway].基于AGE-RAGE信号通路探讨坤泰胶囊治疗多囊卵巢综合征大鼠模型的机制
Zhongguo Zhong Yao Za Zhi. 2024 Feb;49(4):1082-1090. doi: 10.19540/j.cnki.cjcmm.20231115.501.

引用本文的文献

1
The Synergistic Effect of Autophagy and Apoptosis in Iraqi Women with Polycystic Ovary Syndrome.自噬与凋亡在伊拉克多囊卵巢综合征女性中的协同作用
J Reprod Infertil. 2025 Jan-Mar;26(1):36-49. doi: 10.18502/jri.v26i1.18780.
2
Mechanistic insights into the Bushen Huatan Huoxue Formula and its components in ameliorating obesity-associated polycystic ovary syndrome.补肾化痰活血方及其成分改善肥胖相关性多囊卵巢综合征的机制研究
Chin Med. 2025 Jul 1;20(1):99. doi: 10.1186/s13020-025-01165-3.
3
Semaglutide Alleviates Ovarian Oxidative Stress and Autophagy via the PI3K/AKT/mTOR Pathway in Mice with Polycystic Ovary Syndrome.
司美格鲁肽通过PI3K/AKT/mTOR通路减轻多囊卵巢综合征小鼠的卵巢氧化应激和自噬。
Drug Des Devel Ther. 2025 May 23;19:4297-4310. doi: 10.2147/DDDT.S522730. eCollection 2025.
4
The emerging roles of N6-methyladenosine (m6A) deregulation in polycystic ovary syndrome.N6-甲基腺苷(m6A)失调在多囊卵巢综合征中的新作用。
J Ovarian Res. 2025 May 23;18(1):107. doi: 10.1186/s13048-025-01690-7.
5
Inherently imperfect, inherently evolving - The pursuit of precision through biomarkers.本质上不完美,本质上不断演变——通过生物标志物追求精准度。
Biomed J. 2025 Feb;48(1):100839. doi: 10.1016/j.bj.2025.100839. Epub 2025 Feb 25.
6
Impact of high-fructose diet and metformin on histomorphological and molecular parameters of reproductive organs and vaginal microbiota of female rat.高果糖饮食和二甲双胍对雌性大鼠生殖器官的组织形态学和分子参数以及阴道微生物群的影响。
Sci Rep. 2024 Nov 10;14(1):27463. doi: 10.1038/s41598-024-76211-5.
7
Fisetin mitigates letrozole-induced polycystic ovarian syndrome in rats: crosstalk of AMPK/PI3K/AKT-mediated-Nrf2 antioxidant defense mechanism and the inflammasome NLRP3/NF-κB P65/IL-1β signaling pathways.金雀异黄素减轻来曲唑诱导的大鼠多囊卵巢综合征:AMPK/PI3K/AKT 介导的 Nrf2 抗氧化防御机制与 NLRP3/NF-κB P65/IL-1β 信号通路的串扰。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Oct;397(10):8077-8088. doi: 10.1007/s00210-024-03124-5. Epub 2024 May 24.
8
BOP1 contributes to the activation of autophagy in polycystic ovary syndrome via nucleolar stress response.BOP1 通过核仁应激反应促进多囊卵巢综合征中的自噬激活。
Cell Mol Life Sci. 2024 Feb 27;81(1):101. doi: 10.1007/s00018-023-05091-1.
9
Bushenhuoluo Decoction improves polycystic ovary syndrome by regulating exosomal miR-30a-5p/ SOCS3/mTOR/NLRP3 signaling-mediated autophagy and pyroptosis.补肾活络汤通过调节外泌体miR-30a-5p/SOCS3/mTOR/NLRP3信号介导的自噬和焦亡改善多囊卵巢综合征。
J Ovarian Res. 2024 Feb 1;17(1):29. doi: 10.1186/s13048-024-01355-x.
10
Signaling pathways and targeted therapeutic strategies for polycystic ovary syndrome.多囊卵巢综合征的信号通路和靶向治疗策略。
Front Endocrinol (Lausanne). 2023 Oct 19;14:1191759. doi: 10.3389/fendo.2023.1191759. eCollection 2023.